• Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study 

      Sando, Sigrid Botne; Albrektsen, Grethe; Møller, Ina; White, Linda; Berge, Guro; Grøntvedt, Gøril Rolfseng; Lauridsen, Camilla; Bråthen, Geir (Journal article; Peer reviewed, 2016)
      Background α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) ...
    • Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease 

      Patra, Kalicharan; Soosaipillai, Antoninus; Sando, Sigrid Botne; Lauridsen, Camilla; Berge, Guro; Møller, Ina; Grøntvedt, Gøril Rolfseng; Bråthen, Geir; Begcevic, Ilijana; Moussaud, Simon; Minthon, Lennart; Hansson, Oskar; Diamandis, Eleftherios P.; White, Linda Rosemary; Nielsen, Henrietta M. (Journal article; Peer reviewed, 2018)
      Background Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in ...
    • Cerebrospinal fluid A?43 is reduced in early-onset compared to late-onset Alzheimer's disease, but has similar diagnostic accuracy to A?42 

      Lauridsen, Camilla; Sando, Sigrid Botne; Møller, Ina; Berge, Guro; Pomary, Precious Kwadzo; Grøntvedt, Gøril Rolfseng; Salvesen, Øyvind; Bråthen, Geir; White, Linda (Journal article; Peer reviewed, 2017)
      Background: Amyloid beta 1–43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer’s disease (AD). We have investigated cerebrospinal fluid (CSF) levels of Aβ43 in patients with early-onset AD in contrast ...
    • Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study 

      Lauridsen, Camilla; Sando, Sigrid Botne; Shabnam, Adiba; Møller, Ina; Berge, Guro; Grøntvedt, Gøril Rolfseng; Bakken, Inger Johanne; Salvesen, Øyvind; Bråthen, Geir; White, Linda (Journal article; Peer reviewed, 2016)
      Introduction: Biomarkers that will reliably predict the onset of Alzheimer’s disease (AD) are urgently needed. Although cerebrospinal fluid (CSF) amyloid beta 1–42 (Aβ42), total tau, and phosphorylated tau can be used to ...
    • Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years 

      Kirsebom, Bjørn-Eivind; Espenes, Ragna; Hessen, Erik; Waterloo, Knut; Johnsen, Stein Harald; Gundersen, Elisabeth; Sando, Sigrid Botne; Grøntvedt, Gøril Rolfseng; Timón, Santiago; Fladby, Tormod (Journal article; Peer reviewed, 2019)
      Background/Objective: In recent years, several slightly younger cohorts have been established in order to study the preclinical and prodromal phases of dementia. The Consortium to Establish a Registry for Alzheimer’s Disease ...
    • Glial activation and inflammation along the Alzheimer's disease continuum 

      Nordengen, Kaja; Kirsebom, Bjørn-Eivind; Henjum, Kristi; Selnes, Per; Gisladottir, Berglind; Wettergreen, Marianne; Torsetnes, Silje Bøen; Grøntvedt, Gøril Rolfseng; Waterloo, Knut; Aarsland, Dag; Nilsson, Lars; Fladby, Tormod (Journal article; Peer reviewed, 2019)
      Background Neuronal and glial cell interaction is essential for synaptic homeostasis and may be affected in Alzheimer’s disease (AD). We measured cerebrospinal fluid (CSF) neuronal and glia markers along the AD continuum, ...
    • The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease 

      Twohig, Daniel; Rodriguez-Vieitez, Elena; Sando, Sigrid Botne; Berge, Guro; Lauridsen, Camilla; Møller, Ina; Grøntvedt, Gøril Rolfseng; Bråthen, Geir; Patra, Kalicharan; Bu, Guojun; Benzinger, Tammie; Karch, Celeste M.; Fagan, Anne M.; Morris, John C.; Bateman, Randall J.; Nordberg, Agneta; White, Linda Rosemary; Nielsen, Henrietta M. (Journal article; Peer reviewed, 2018)
      Accumulating evidence demonstrating higher cerebrospinal fluid (CSF) α-synuclein (αSyn) levels and αSyn pathology in the brains of Alzheimer’s disease (AD) patients suggests that αSyn is involved in the pathophysiology of ...